Solid Dosage
GEA can supply the right technology for Manufacturing Solid Dosage Forms for Gastrointestinal Applications, incl. high-volume production, effervescent processing and MUPS.
Comprising a varied landscape of antacids, antiulcerants, vitamins and minerals, antiemetics, antinauseants, antidiarrheals and anti-obesity products, the gastrointestinal drugs market is segmented into a variety of oral solid dosage forms that require a wide range of different production techniques.
For example, for products that have to act in the stomach, effervescent dosages are often preferred. By contrast, for products that have to act in the intestines, MUPS or coated tablets are more prevalent.
Many of these products have to be produced in high volumes as they represent a large portion of the over-the-counter (OTC) market.
Whatever your application, GEA can supply the right equipment and technology for your production requirements: from integrated granulation lines for high-volume production and single-pot processors adapted to effervescent processing to tablet presses that can handle MUPS or effervescent formulations.
For coating applications, available technologies include fluid bed coating for smaller particles, such as powders, granules, seeds, crystals, pellets and small tablets, a multipurpose processor that uses proven fluid bed technology to achieve granulation, drying and pellet coating (or tablet coating) in a single processor and a continuous tablet coater that accurately deposits controlled amounts of coating materials on tablets, even if they are hygroscopic or friable.
Affichage de 4 sur 26

En tant qu’intégrateurs de systèmes, nous associons notre savoir faire en matière de technologie de process et d'engineering aux logiciels de contrôle commande et de supervision développés par des leaders du marché.

Contained Materials Handling solutions for Primary and Secondary Pharmaceuticals and Healthcare. With extensive experience within the generics sector, supply a wide range of technologies and equipment that improve and enhance the efficiency and performance of Oral Solid Dosage production.

The ConsiGma® DC for direct compression is the latest expansion of GEA's continuous portfolio for cost effective, compact, high yield manufacturing systems. It offers a robust and flexible manufacturing method for a wide range of products.

Continuous Processing is becoming more and more important in the pharmaceutical industry. GEA takes the lead in introducing this innovative technology with ConsiGma® - continuous high-shear granulation and drying lines.
GEA’s past fiscal year was one of significant growth and further profitability gains. In particular, the technology group substantially increased order intake, with all divisions contributing here. GEA also made progress in all Mission 30 strategic growth areas. In addition, GEA met key interim targets under its climate plan ahead of schedule. Major milestones in fiscal year 2025 were admission to the DAX index, the award of one of the largest contracts in the company’s history, and streamlining of the corporate structure.
Grâce à un nouveau site de fabrication, le SmartParc, des transformateurs de produits alimentaires du Royaume-Uni diminuent leurs dépenses courantes et leurs émissions. S'appuyant sur la technologie de chauffage et de refroidissement de GEA, ce modèle de production collaboratif démontre comment l'innovation accélère les ambitions « zéro net » de l'industrie.
« Brasser des œufs, c'est comme brasser de la bière. » C'est le genre de comparaison qui fait sourire, puis qui fait tilt : Quelque chose qui semblait complexe devient soudain simple. Dans ce film personnel, qui se déroule dans le cœur agricole des États-Unis, nous explorons la fermentation de précision et le travail concret qu'il faut accomplir pour transformer une idée en nourriture.